Vis enkel innførsel

dc.contributor.authorStausholm, Martin Bjørnen_US
dc.contributor.authorNaterstad, Ingvill Fjellen_US
dc.contributor.authorJoensen, Jonen_US
dc.contributor.authorLopes-Martins, Rodrigo Álvaro Brandãoen_US
dc.contributor.authorSæbø, Humairaen_US
dc.contributor.authorLund, Hansen_US
dc.contributor.authorFersum, Kjartanen_US
dc.contributor.authorBjordal, Jan Magnusen_US
dc.date.accessioned2020-08-05T09:41:56Z
dc.date.available2020-08-05T09:41:56Z
dc.date.issued2019
dc.PublishedStausholm MB, Naterstad IF, Joensen JJ, Lopes-Martins RÁB, Sæbø H, Lund H, Fersum K, Bjordal JM. Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: Systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2019;9(10):e031142eng
dc.identifier.issn2044-6055
dc.identifier.urihttps://hdl.handle.net/1956/23441
dc.description.abstractObjectives: Low-level laser therapy (LLLT) is not recommended in major knee osteoarthritis (KOA) treatment guidelines. We investigated whether a LLLT dose–response relationship exists in KOA. Design: Systematic review and meta-analysis. Data sources: Eligible articles were identified through PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature, Physiotherapy Evidence Database and Cochrane Central Register of Controlled Trials on 18 February 2019, reference lists, a book, citations and experts in the field. Eligibility criteria for selecting studies: We solely included randomised placebo-controlled trials involving participants with KOA according to the American College of Rheumatology and/or Kellgren/Lawrence criteria, in which LLLT was applied to participants’ knee(s). There were no language restrictions. Data extraction and synthesis: The included trials were synthesised with random effects meta-analyses and subgrouped by dose using the World Association for Laser Therapy treatment recommendations. Cochrane’s risk-of-bias tool was used. Results: 22 trials (n=1063) were meta-analysed. Risk of bias was insignificant. Overall, pain was significantly reduced by LLLT compared with placebo at the end of therapy (14.23 mm Visual Analogue Scale (VAS; 95% CI 7.31 to 21.14)) and during follow-ups 1–12 weeks later (15.92 mm VAS (95% CI 6.47 to 25.37)). The subgroup analysis revealed that pain was significantly reduced by the recommended LLLT doses compared with placebo at the end of therapy (18.71 mm (95% CI 9.42 to 27.99)) and during follow-ups 2–12 weeks after the end of therapy (23.23 mm VAS (95% CI 10.60 to 35.86)). The pain reduction from the recommended LLLT doses peaked during follow-ups 2–4 weeks after the end of therapy (31.87 mm VAS significantly beyond placebo (95% CI 18.18 to 45.56)). Disability was also statistically significantly reduced by LLLT. No adverse events were reported. Conclusion: LLLT reduces pain and disability in KOA at 4–8 J with 785–860 nm wavelength and at 1–3 J with 904 nm wavelength per treatment spot.en_US
dc.language.isoengeng
dc.publisherBMJeng
dc.rightsAttribution-Non Commercial CC BY-NCeng
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/eng
dc.titleEfficacy of low-level laser therapy on pain and disability in knee osteoarthritis: Systematic review and meta-analysis of randomised placebo-controlled trialsen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2020-02-10T09:54:18Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2019 The Authors
dc.source.articlenumbere031142
dc.identifier.doihttps://doi.org/10.1136/bmjopen-2019-031142
dc.identifier.cristin1755970
dc.source.journalBMJ Open
dc.identifier.citationBMJ Open. 2019, 9 (10), e031142.
dc.source.volume9
dc.source.issue10


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-Non Commercial CC BY-NC
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-Non Commercial CC BY-NC